Enzyme ImmunoAssay (ELISA) for the determination of IgM class antibodies to Hepatitis Delta Virus or HDV in human plasma and sera with the "capture" system. The kit is intended for the classification of the viral infective agent and the follow-up of HDV infected patients

Regulatery Status: CE
Catalog No Size
Product Catalog No: DIM Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

The Hepatitis Delta Virus or HDV is a RNA defective virus composed of a core presenting the delta-specific antigen, encapsulated by HBsAg, that requires the helper function of HBV to support its replication.

Infection by HDV occurs in the presence of acute or chronic HBV infection. When acute delta and acute HBV simultaneously occur, the illness becomes severe and clinical and biochemical features may be indistinguishable from those of HBV infection alone. In contrast, a patient with chronic HBV infection can support HDV replication indefinitely, usually with a less severe illness appearing as a clinical exacerbation. The determination of HDV specific serological markers (HDV Ag, HDV IgM and HDV IgG) represents in these cases an important tool to the clinician for the classification of the etiological agent, for the follow up of infected patients and their treatment.

The detection of HDV IgM and IgG antibodies allows the classification of the illness and the monitoring of the seroconversion event.

Test Principle

Microplates are coated with a monoclonal anti-hIgM antibody that in the 1st incubation “captures” specifically this class of antibodies.

After washing out all the other components of the sample, in the 2nd incubation bound anti HDV IgM are detected by the addition of recombinant HDV antigen immunocomplexed with a specific antibody, labeled with peroxidase (HRP).

After washing, the enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of IgM antibodies present in the sample.

Order Enquiry

Order Enquiry Form

References
  1. Engvall E. and Perlmann P.. J.Immunochemistry 8: 871- 874, 1971
  2. Engvall E. and Perlmann P.. J.Immunol.. 109: 129-135, 1971
  3. Chaggar K. Et al.. Journal of Virological Methods. 32: 193- 199, 1991
  4. Lazinski D.W. et al.. Journal of Virol.. 67: 2672-2680, 1993
  5. Govindarajan S. et al.. Microbiol. And Immunol.. 95: 140- 141, 1990
  6. Shattock A.G. et al.. J.Clin.Microbiol.. 29: 1873-1876, 1991
  7. Forbes B.A. et al.. Clin.Microbiol.News.. 13: 52-54, 1991
  8. Bergmann, K. et al. J.Immunol. 143:3714-3721, 1989
  9. Bergmann, K. et al. J.Infect.Dis. 154:702-706, 1986
  10. Buti, M. et al. Hepatology 8:1125-1129, 1988
  11. Rizzetto, M. Hepatology 3729-737, 1983
  12. Rizzetto, M. et al. Proc.Natl.Acad.Sci. USA 77:6124-6128, 1980
  13. Dubois, F. et al. J.Clin.Microbiol. 26:1339-1342, 1988
  14. Wang, K. et al. Nature 323:508-514, 1986
  15. Grebenchtchikiov N. et al.. J.Immunol. Methods, 15(2) :219-231, 2002
  16. Schrijver RS and Kramps JA, Rev.Sci.Tech. 17(2):550- 561, 1998
Enquiry